Qingdao Jianma Gene Technology Co., Ltd. was established in February 2019，Located in the Industrial Technology Research Institute of Qingdao High-tech Zone, Shandong Province，It is a scientific and technological enterprise focusing on the R&D and production of medical devices in the molecular POCT field.
The company is equipped with a 100,000-level purification workshop and international leading scientific research equipment and production equipment, and has a 1,200 square meter research and development and production workshop.
A complete quality management system has been established to meet the requirements of laws, regulations and standardized production.
The company has two unique nucleic acid detection technology platforms(Isothermal nucleic acid detection platform, ASEA nucleic acid rapid detection platform)，Products developed based on this platform have the characteristics of simplicity, speed, high specificity, and high sensitivity.
It has been successfully applied to many fields such as medical health, food safety, animal disease and so on.
Develop handheld microfluidic detection chips with stable performance and high specificity that do not rely on complex instruments.The above two topics have laid a good technical foundation for the company's molecular POCT products, and are an important source of topics for the company's molecular rapid inspection products to enter the market.
New requirements for the prevention and control of the SARS-CoV-2 epidemic and the status quo of enterprise
As the global epidemic continues to evolve, epidemic prevention and control has entered a stage of normalization.
In order to properly respond to the current situation and meet the requirements of nucleic acid testing in different scenarios,It is necessary to speed up research and development and production organization, launch more integrated and quick-test products suitable for on-site testing, and improve my country's nucleic acid testing products and technical systems.
On July 29, Premier Li Keqiang hosted an executive meeting of the State Council.In order to ensure the overall planning of epidemic prevention and development, arrangements have been made to further strengthen the building of nucleic acid testing capabilities.
The meeting pointed out that it is necessary to mobilize all parties to accelerate the development and launch of products with short time, high sensitivity and easy operation.Intensify the training of inspection personnel and increase the mobile inspection force reasonably,For the nucleic acid testing of patients in fever clinics, try to shorten the report to 4 hours.
During the outbreak of the SARS-CoV-2 epidemic, the Jianma Gene Technology Co., Ltd. team worked with Qingdao University of Science and Technology and Qingdao University to research key problems, develop nucleic acid detection products, and achieve detection in about 30 minutes.
On March 13, 2020, the COVID-19 kit obtained the EU CE certification;On May, obtained the export qualification of the new crown testing reagent manufacturer of the Ministry of Commerce of China.
The single-use virus sampling tube developed by our company only takes 3 minutes to complete sample processing and rapid extraction.At present, the filing and production filing of Class I medical device products have been completed.The rapid nucleic acid detection products developed by the company shorten the nucleic acid detection time to 30 minutes, which fully meets the national epidemic prevention and control needs and social needs.At present, COVID-19 rapid test products have been exported to Indonesia, Brazil and other countries, and have been recognized by customers.